MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial

[1]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[2]  R. Collins,et al.  MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomised placebo-controlled trial , 2002 .

[3]  Tw.  MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial , 2002, The Lancet.

[4]  J. Pasco,et al.  Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study. , 2002, Archives of internal medicine.

[5]  Jennie Chang,et al.  Cerivastatin and reports of fatal rhabdomyolysis. , 2002, The New England journal of medicine.

[6]  Kenneth Rockwood,et al.  Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. , 2002, Archives of neurology.

[7]  Catherine Sudlow,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[8]  A. Coats.  MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial , 2002 .

[9]  E. Bolson,et al.  Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. , 2001, The New England journal of medicine.

[10]  D. Waters,et al.  Low-density-lipoprotein cholesterol goals for patients with coronary disease: treating between the lines. , 2001, Circulation.

[11]  K. Yano,et al.  Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study , 2001, The Lancet.

[12]  J Tuomilehto,et al.  Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study , 2001, BMJ.

[13]  P. Sandercock.  Statins for stroke prevention? , 2001, The Lancet.

[14]  A. Bayer,et al.  Age and gender bias in statin trials. , 2001, QJM : monthly journal of the Association of Physicians.

[15]  R. Collins,et al.  Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials , 2001, The Lancet.

[16]  B. Davis,et al.  Reduction of Stroke Events With Pravastatin: The Prospective Pravastatin Pooling (PPP) Project , 2001, Circulation.

[17]  S. Manuck,et al.  Cholesterol reduction and non-illness mortality: meta-analysis of randomised clinical trials , 2001, BMJ : British Medical Journal.

[18]  F. Palace,et al.  Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries , 2001 .

[19]  I. Reid,et al.  Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease. , 2001, Lancet.

[20]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[21]  B Neal,et al.  Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials , 2000, The Lancet.

[22]  H Jick,et al.  Statins and the risk of dementia , 2000, The Lancet.

[23]  A. Keech,et al.  Effect of Pravastatin on Coronary Disease Events in Subgroups Defined by Coronary Risk Factors: The Prospective Pravastatin Pooling Project , 2000, Circulation.

[24]  J. Armitage,et al.  Need for large scale randomised evidence about lowering LDL cholesterol in people with diabetes mellitus: MRC/BHF heart protection study and other major trials , 2000, Heart.

[25]  Michael J. Goodman,et al.  Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women , 2000, The Lancet.

[26]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[27]  Ames,et al.  PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA , 2000 .

[28]  M. Prince,et al.  The development and initial validation of a telephone‐administered cognitive test battery (TACT) , 1999 .

[29]  R. Collins,et al.  MRC BHFHeart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience , 1999 .

[30]  J. Welch.  MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. , 1999, European heart journal.

[31]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[32]  G. Mancia,et al.  Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. , 1998, Atherosclerosis.

[33]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[34]  G. Thorgeirsson,et al.  Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S) , 1998, Circulation.

[35]  P. Macfarlane,et al.  Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). , 1998, Circulation.

[36]  B. Davis,et al.  Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. , 1998, Circulation.

[37]  A. Weverling-Rijnsburger,et al.  Total cholesterol and risk of mortality in the oldest old , 1997, The Lancet.

[38]  Post Coronary Artery Bypass Graft Trial Investigators.  The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. , 1997, The New England journal of medicine.

[39]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[40]  S. Hulley,et al.  Carcinogenicity of Lipid-Lowering Drugs-Reply , 1996 .

[41]  S. Hulley,et al.  Carcinogenicity of lipid-lowering drugs. , 1996, JAMA.

[42]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[43]  S. Devaraj,et al.  Comparison of an immunoprecipitation method for direct measurement of LDL-cholesterol with beta-quantification (ultracentrifugation). , 1995, American journal of clinical pathology.

[44]  M. Pfeffer,et al.  Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens. Cholesterol Treatment Trialists' (CTT) Collaboration. , 1995, The American journal of cardiology.

[45]  M. Schroll,et al.  Stroke incidence, case fatality, and mortality in the WHO MONICA project. World Health Organization Monitoring Trends and Determinants in Cardiovascular Disease. , 1995, Stroke.

[46]  C. A. Ferguson,et al.  Immunoseparation method for measuring low-density lipoprotein cholesterol directly from serum evaluated. , 1995, Clinical chemistry.

[47]  Scandinavian Simvastatin Survival Study Group.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.

[48]  J. Neaton,et al.  Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial , 1993, Diabetes Care.

[49]  T. Prout,et al.  C-peptide and the classification of diabetes mellitus patients in the Early Treatment Diabetic Retinopathy Study. Report number 6. The ETDRS Research Group. , 1993, Annals of epidemiology.

[50]  S. Yusuf,et al.  Report of the Conference on Low Blood Cholesterol: Mortality Associations , 1992, Circulation.

[51]  L Wilhelmsen,et al.  Cholesterol and total mortality: need for larger trials. , 1992, BMJ.

[52]  G. Davey Smith,et al.  Should there be a moratorium on the use of cholesterol lowering drugs? , 1992, BMJ.

[53]  N. Cook,et al.  Estimating the effect of the run-in on the power of the Physicians' Health Study. , 1991, Statistics in medicine.

[54]  R Peto,et al.  Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. , 1991, BMJ.

[55]  M. Oliver.  Might treatment of hypercholesterolaemia increase non-cardiac mortality? , 1991, The Lancet.

[56]  K. Matthews,et al.  Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. , 1990, BMJ.

[57]  R. Peto,et al.  Beta blockade during and after myocardial infarction: an overview of the randomized trials. , 1985, Progress in cardiovascular diseases.

[58]  A. V. Peterson,et al.  Serum cholesterol, other risk factors, and cardiovascular disease in a Japanese cohort. , 1984, Journal of chronic diseases.

[59]  L. Freedman,et al.  Allocation of patients to treatment groups in a controlled clinical study. , 1978, British Journal of Cancer.

[60]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[61]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.